Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Conformational Polymorphism of m7GTP in Crystal Structure of the PB2 Middle Domain from Human Influenza A Virus

  • Toshiharu Tsurumura ,

    Contributed equally to this work with: Toshiharu Tsurumura, Hao Qiu

    Affiliation Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto, Japan

  • Hao Qiu ,

    Contributed equally to this work with: Toshiharu Tsurumura, Hao Qiu

    Affiliation Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto, Japan

  • Toru Yoshida,

    Affiliation Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto, Japan

  • Yayoi Tsumori,

    Affiliation Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto, Japan

  • Dai Hatakeyama,

    Affiliation Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan

  • Takashi Kuzuhara,

    Affiliation Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan

  • Hideaki Tsuge

    Affiliation Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto, Japan

Conformational Polymorphism of m7GTP in Crystal Structure of the PB2 Middle Domain from Human Influenza A Virus

  • Toshiharu Tsurumura, 
  • Hao Qiu, 
  • Toru Yoshida, 
  • Yayoi Tsumori, 
  • Dai Hatakeyama, 
  • Takashi Kuzuhara, 
  • Hideaki Tsuge


Influenza pandemics with human-to-human transmission of the virus are of great public concern. It is now recognized that a number of factors are necessary for human transmission and virulence, including several key mutations within the PB2 subunit of RNA-dependent RNA polymerase. The structure of the middle domain in PB2 has been revealed with or without m7GTP, thus the middle domain is considered to be novel target for structure-based drug design. Here we report the crystal structure of the middle domain of H1N1 PB2 with or without m7GTP at 1.9Å and 2.0Å resolution, respectively, which has two mutations (P453H, I471T) to increase electrostatic potential and solubility. Here we report the m7GTP has unique conformation differ from the reported structure. 7-methyl-guanine is fixed in the pocket, but particularly significant change is seen in ribose and triphosphate region: the buried 7-methyl-guanine indeed binds in the pocket forming by H357, F404, E361 and K376 but the triphosphate continues directly to the outer domain. The presented conformation of m7GTP may be a clue for the anti-influenza drug-design.


Influenza virus is an RNA virus belonging to the Orthomyxoviridae family, characterized by eight segments of viral RNA. In humans, seasonal influenza virus causes respiratory inflammation, high fever, head and muscle aches, and fatigue. However, during the 1918 pandemic, the influenza virus (known as the Spanish influenza) also caused severe pneumonia, and an estimated 50 million died worldwide [1]. Including that event, there have been four pandemics: the Spanish influenza (H1N1) in 1918/1919, Asian influenza (H2N2) in 1957, Hong Kong influenza (H3N2) in 1968 and H1N1 influenza in 2009. Within the influenza virus, three RNA-polymerase proteins (PA, PB1 and PB2), the nucleoprotein (NP) and the viral RNAs form the ribonucleoprotein (RNP) complex [2]. The polymerases within this complex catalyze the transcription and replication of the viral genome, while NP forms an oligomerization complex to stabilize the vRNA. Among the polymerases, PB1 plays the central role in RNA polymerization. PB2 mediates the cap-snatching mechanism; i.e., it binds the capped mRNA of the host for transcription of the influenza genome. And PA acts as a nuclease, cleaving the capped mRNAs to produce 13- to 15-mers, which serve to prime viral mRNA transcription [3].

The structure of the RNP complex were investigated using cryogenic electron microscopy [4,5], however, there have been no structural analyses of the entire RNP complex or the RNA polymerase complex at the atomic level. Partial domain structures of the RNA polymerase subunit have been reported [6-11]. In PB2, substitutions at positions 627 of PB2 have been reported to be important for the adaptation of the avian virus to mammalian hosts [12-14]. The crystal structures of the large C-terminal domain of PB2, including this E627K mutation, which enables human infection, were reported by us and other [6,15]. Our structure is the first deposited structure of a PB2 domain containing the pathogenicity determinant lysine 627 in the Protein Data Bank (2008 Apr 21) and we also revealed the RNA binding ability of this domain which is strengthened by the E627K mutation [15]. On the other hand, though several potential cap binding sites had been postulated based on crosslinking and mutagenesis experiments: 242-252 as N-site [16], 533-577 as C-site [16,17] and a more central site as M-site [18], the complex structural analysis with m7GTP showed that the cap-binding sites is the middle domain of PB2 [19]. Recently further structures of the PB2 middle domain from three strains were reported; human H1N1 middle domain without m7GTP, human H3N2 middle domain with m7GTP and human H5N1 middle domain with m7GTP [20].

Here we report PB2 middle domain structure (318-483) belonging to subtype H1N1 human influenza with m7GTP (Figure 1), which has two mutations (P453H, I471T) to increase solubility of this domain. Though the whole structure of PB2 middle domain is basically the similar as the reported structure, the appeared conformation of m7GTP is different from the reported one. We discuss about the m7GTP conformation which would be important for the drug design.

Figure 1. Crystal structure of PB2 middle domain (amino acids 318 to 483) of H1N1 from human influenza A virus with or without m7GTP.

A) Crystal structure without m7GTP in magenta. Left panel is the overall structure. Right panel is the same model as left panel but rotated by 60° about a horizontal axis to show the active site. Secondary structures are labeled in black and two mutations P453H and I471T are indicated by arrows with blue and red labels, respectively. B) Close-up view of the square of panel A in stereo view. Main chain is represented by white ribbon. Residues of active site and N-terminal helix are labeled in black. C) Crystal structure with m7GTP in green. Left panel is the overall structure. Right panel is the same model as left panel but rotated by 60° about a horizontal axis to show the active site. m7GTP is represented by stick model. Secondary structures are labeled in black and two mutations P453H and I471T are indicated by arrows with blue and red labels, respectively. D) Close-up view of the square of panel of C in stereo view. Main chain is represented by white ribbon. Active site residues are labeled in black. H357, F404, E361 and K376 formed the active site cleft to bind to 7-methyl-guanine. Triphosphate interacts with R332, S337, K339, R355 and E361.


Properties of the middle domain of PB2 (H1N1)

We initially purified His-tagged PB2 middle domain using a nickel chelate column [19]. However, the fraction eluted with 200 mM NaCl was not stable, and aggregation of the protein could be seen. We therefore modified the protocol to elute the protein with 500 mM NaCl and found that the PB2 (H1N1) middle domain was stable under these high salt conditions. Next we considered to change the surface electrostatic potential and to increase the middle domain solubility by mutations. Two mutations (P453H and I471T) were introduced because these positions are surface of the protein and far from cap-binding site. These mutations increased the solubility so that the final protein was stable in 50 mM Tris-HCl (pH 8.0), 200 mM NaCl. Crystals appeared in two or three days and reached to ~0.3mm size. We collected the native data sets at 2.00 Å resolution with in-house X-ray generator and detector (Table 1). We also collected the data set of m7GTP soaked crystal in 0.5 mM m7GTP for 2.5 hours, at 1.93 Å (Table 1). The upper limit resolution of these data were carefully chosen including the recent discussion of CC1/2 [21]. The final Rwork (Rfree) of apo and m7GTP-bound form were 18.6% (22.8%) and 17.8% (21.2%), respectively.

Data collection
Apo formm7GTP-bound form
Unit cell (Å)a=107.8, b=107.8, c=136.6a=107.6, b=107.6, c=138.3
Space groupR32R32
Resolution (Å)20.98-2.00 (2.07-2.00)18.88-1.93 (2.00-1.93)
Total number of reflections225,288(20,870)166,528 (15,742)
Number of unique reflections20,909 (2,041)23,160 (2,272)
Completeness (%)99.8 (98.3)99.06 (99.43)
Rmerge0.104 (1.055)0.058 (0.622)
Rmeas0.109 (1.110)0.063 (0.673)
Rpim0.033 (0.346)0.023 (0.253)
I/sigma(I)24.8 (3.2)29.3 (4.4)
Redundancy10.8 (10.2)7.19 (6.93)
CC1/20.999 (0.698)0.999 (0.782)
RMSD bond length0.0070.006
RMSD bond angle1.0321.076
Number of atoms in the model1,5291,555
Number of water molecules185233
Number of residues in outlier region of Ramachandran plot00
The average B-factor33.534.2

Table 1. Data collection and structure refinement statistics of PB2 middle domain.

Values in parentheses are for the last resolution shell.
Rmerge = ∑hkli|li(hkl) - <l(hkl)>|lhkli|li(hkl)|
Rmeas = ∑hkl[N/(N-1)]1/2i|li(hkl)-<l(hkl)>|lhkli li(hkl)
Rpim = ∑hkl[1/(N-1)]1/2i|li(hkl)-<l(hkl)>|lhkli li(hkl)
where li(hkl) is the intensity measurement for a reflection hkl,
<l(hkl)> is the mean intensity for this reflection and N is Redundancy.
CC1/2 is calculated according to the formula in Ref. 21.
Rwork= ∑hkl||Fobs| - |Fcalc||lhkl|Fobs|.
Rfree was calculated with randomly selected reflections (5%).
Download CSV

Structure of the H1N1 PB2 Middle Domain

There was one molecule in an asymmetric unit (Figure 1). This crystal contains large solvent content (70%), and two mutations P453H and I471T located on the solvent accessible surface in the crystal packing. The similar minimal cap binding domain structure has been revealed before (2VQZ). The overall fold was the same as reported structure: a four helix bundle (α1 ~ α4) was wrapped by three parts of β-sheet ((1) β1, β2, β5, β6 and β7 (2), β8 〜 β12 and (3) β3 ~ β4). However, compared with the reported structure of PB2 middle domain, in native, one large structural change could be seen: N-terminal region formed one additional α-helix which consists of 315SHMRISS321 (Figure 1 and Figure 2). The first three residues (315SHM317) are additional residues derived from pET15b vector. The side chain of H316 interacts with S336 and it seems to stabilize this α-helix. On the other hand, by m7GTP soaking, the α-helix deformed to a flexible structure as describe later. The RMSD value is 1.00 Å between native and m7GTP using all identical atoms. A homology structural search using DALI [22] showed no strong similarity with any other proteins except 2VQZ. This is also true for the PB2 large C-terminal domain, which shows no strong similarity to any other proteins. Apparently influenza A virus PB2 is very distant from other proteins, at least based on its structural classification.

Figure 2. Electron densities of the active sites in stereo view.

The molecular orientation is the same as bottom view in Figure 1. The 2Fo-Fc electron density maps are drawn at one sigma. A) The active site of m7GTP-bound form. The electron density of m7GTP and the active site residues are represented in yellow mesh and green mesh, respectively. 6B) The active site without m7GTP. The electron density of additional N-terminal helix and the active site residues are represented in cyan mesh and magenta mesh, respectively.

Conformational Polymorphism of m7GTP

The crystal was soaked in 0.5 mM m7GTP solution for 2.5 hours. The 2Fo-Fc electron density of m7GTP was explicitly visible (Figure 2). Compared with the reported structure (Figure 3), it shows the similar conformation that 7-methyl-guanine is fixed in the deep cleft forming by H357, F404, E361 and K376. However, particularly significant change was seen in ribose and triphosphate region. In reported structure (2VQZ), the triphosphate is bent around the base with the α-phosphate interacting with H432 and N429 and the γ-phosphate interacting with H357 and, K339 and R355 (Figure 3). In our structure, such bent could not be seen because the ribose rotated via N9 and C1 so the triphosphate continues directly to the outer domain (Figure 1C, D left direction). Interestingly, compared with native structure, the N-terminal α-helix deformed to a flexible structure upon the soaking of m7GTP, thus the triphosphate lies in the same region instead of α-helix. It is important to note that the N-terminal region is flexible with no electron density, so the conformation m7GTP is not affected by these N-terminal residues. Furthermore, in two more structures of PB2 middle domain with m7GTP, all m7GTP conformation is the same as that in 2VQZ [19]. Conformational features of the presented m7GTP are listed as follows: (1) the side chain of R355 and K339 changed the direction to hold the triphosphate. The feature is not seen in other PB2 middle domain structures with m7GTP (2). The side chain of H357 moves from apo to holo state to interact with 7-methyl-guanine via π-π interaction (3). The conformation of m7GTP in 2VQZ shows the interaction with N429, M431 and H432, but the presented structure shows no interaction with these residues.

Figure 3. Comparison the m7GTP-bound form in H1N1 (this report) and H3N2 (2VQZ).

A) Crystal structure in H1N1 and H3N2 are shown in green and yellow, respectively. Both m7GTPs are depicted with stick model. Upper panel is the overall structure and lower panel is the bottom view with 60° orientation of upper panel. B) Close-up view of the square of panel A in stereo view. Main chain is represented by ribbon. Active site residues are labeled in black. C) Comparison the conformation of m7GTP in H1N1 and H3N2 structure. Left panel is same orientation as A and B. Right panel is the same model as left panel but rotated by 60° about a horizontal axis to show the active site.. The position of ribose and triphosphate are labeled in each color. The 7-methyl guanine is same conformation and it is labeled in black.


P453H mutation increased the surface basic electrostatic potential drastically

In Figure 4, we showed the sequence differences of PB2 middle domain of avian influenza H1N1 and human influenza H1N1, H2N2 and H3N2. In the whole PB2 sequence, it was reported that seventeen substitutions, which are highly conserved in avian or human, would be candidates to enable to cross the barrier between the species from avian to human as an adaptive mutant [23]. In addition to the seventeen characteristic sites, they reported that two more additional characteristic sites unique to the H1N1 (human), and nine unique to the HxN3 (H2N2/H1N2/H3N2, human). These eleven variants would be also candidates which are needed to cross the species barrier between avian H1N1 and human HxN2. There are no overlap between these sites and the former seventeen mutations [23]. Within former seventeen substitutions, seven sites at position 567, 588, 613, 627, 661, 674, and 702 are highly conserved in the C-terminal domain of PB2. Especially, at 627 position, glutamate is conserved in avian H1N1 with 99.31% and lysine is conserved in human H1N1 and HxN2 with 99.76% [23]. E627K mutation dramatically increased basic charge on the surface. It facilitated the adaptation of H5N1 and other avian viruses to mammals and increased their transmission and/or pathogenicity in humans, mice, ferrets and guinea pigs [24]. Within the PB2 middle domain, there are each two sites with the change from avian to human (residues 368 and 475 (1st human isolate in 1940 and 1918, respectively)) and from avian to H2N2/H3N2 (residues 382 and 453 (1st human isolate in 1961 and 1940, respectively)) [23]. These sites are not in the vicinity of the cap-binding site. Among these four sites, the mutation at position 453 is particularly interesting because it is so drastic, going from proline (H1N1) to histidine (H3N2), though other mutations occur within similar character such as basic (R368K) or hydrophobic (I382V). The P453H mutation first appeared in 1940. Residue 453 is Pro (or Ser) with 98.29% conservation in avian H1N1, and His is conserved in human HxN2 with 99.49%. Thus, based on the characteristic features of P453H mutation, it might be more possible candidate than the others for an adaptive mutation from avian to human HxN2 [23]. In this report, we observed that the PB2 middle domain with two mutations (P453H and I471T) change the solubility and finally we obtained good diffraction crystals by these mutations. It has been well known that the electrostatic surface change by the single E627K mutation enhanced the virulence [15], though it is still open question what is the role of K627 in the RNP complex. Whether the P453H mutation is linked to the viral specific feature of H2N2 or H3N2 is an important issue to be addressed. Given that the histidine at 453 is present in H2N2 or H3N2 but not H1N1, this site may contact with other components such as RNA, PB2, PB1, PA, NP and nuclear export protein [25].

Figure 4. Sequence alignment of the PB2 middle domains.

Avian strain is shown in grey (A/mallard/Tennessee/11464/1985 (H1N1)). Human influenza virus is shown in black: H1N1 (A/Brevig Mission/1/1918), H1N1 (A/Puerto Rico/8/1934), H2N2 (A/Albany/20/1957), and H3N2 (A/Victoria/3/1975) as 2VQZ. The blue and red boxes are the mutation sites at 453 and 471 (See details in the text). Twelve β-strands and four α-helices are depicted in hot pink arrows and light blue bar, respectively.

Importance of m7GTP Conformation in the Trimeric RNA-Polymerase Complex

The novel conformation of m7GTP we presented will be important clue for drug design targeting the cap-binding site. It should be noticed again that two mutations (P453H and I471T) we introduced are totally opposite surface against cap-binding site, thus they does not influence the conformational polymorphism of m7GTP (original (2VQZ) and novel site (this report)).

As we applied m7GTP by crystal soaking, the conformation of soaked compound may be restricted by crystal packing. Thus we checked next points about the phosphate binding site: (1) Original site was preserved in our crystal statically: 7-methyl guanine occupies the same site, but phosphate binds in different manner. There is no direct disturbance to bind phosphate in original site in our crystal. In the original site, important residues for the phosphate binding (H432 and N429) did not change the position (2). Original site was preserved in our crystal dynamically: In comparison with B-factor plot of four different PB2 structure with m7GTP, there are two regions (338 region and 424 loop region) with large difference (Figure 5A). It is considered that these regions are candidate which are influenced by crystal packing. In the same figure, the binding residues were plotted. It shows the phosphate binding site (H432 and N429) are not influenced because they are outside the 338 and 424-loop region. Furthermore, though the phosphate binds R332, S337 and K339 on the 338 region in our structure, we checked that the 338 region of our crystal is not restricted by molecular packing. Based on these facts, we concluded that the novel site is not artifact by the soaking and crystal packing.

Figure 5. B-factor plot for Cα carbons in m7GTP-bound structures.

A) B-factor of the structure in this report is plotted in green, 2VQZ is in magenta, 4EQK is in cyan and 4ES5 is in orange. Active site residues are indicated by vertical lines and labeled in black. B) Mean B-factor values of whole molecule without m7GTP (cyan), m7GTP only (magenta) and active site residues bound to m7GTP (green). C) Changes of B-factor values of the active site residues between apo (blue) and m7GTP (red).

In our crystal, there was less interaction between the molecules because solvent content is 70%. On the other hand, in other crystals (2VQZ and E4S5), the solvent content are ~54%. Average B-factor of our crystal might be the relatively high B-factor compared with 4ES5 (H5N1), but is almost similar compared with 4EQK (H3N2) (Figure 5B). This is the first report with or without m7GTP using the same crystal form. B-factors of some residues around m7GTP (S332, S337, R355, H357, E361 and K376) are suppressed upon m7GTP binding (Figure 5C).

In the first PB2 middle domain structural paper, it suggested the possibility of the different conformation of triphosphate in the context of a capped oligonucleotide. In electrostatic surface of the cap-binding site (Figure 6), we could see channels with strong basic charge in two regions. One region includes R335, K339, K331 and R332 (channel I) and the other region includes R423 on the 424-loop, R436 and R368 (channel II). We observed that the capped-oligonucleotide interacts with channel I in the conformation, but we don’t deny the possibility the continuous RNA interacts with channel II in the trimeric RNA-polymerase complex (Figure 6). We still don’t know which way the capped-oligonucleotide goes through in the trimeric RNA-polymerase complex and this will be next important issue to be addressed.

Figure 6. Electrostatic surfaces of the PB2 middle domain.

A) Apo form and B) m7GTP-bound form in H1N1 and C) m7GTP-bound form in H3N2. The molecular orientation is the same as bottom view in Figure 1 and Figure 3. Yellow arrows show the channels, which might bind the continuous RNA. Electrostatic surfaces were calculated and displayed using PyMOL.

Materials and Methods

Gene cloning, expression and protein purification

The pb2 gene (RIKEN) was inferred from the amino acid sequence of influenza virus H1N1 (A/Puerto Rico/8/1934). We used DNA encoding residues 318-483 subcloned into pET15b vector between the NdeI and BamHI sites. The PB2 middle domain (318-483) was then expressed with an N-terminal histidine-tag and a thrombin cleavage site in E. coli BL21-CoDonPlus-RIL cells (Agilent Technologies) growing in LB medium. The protein was purified by affinity capture on a Ni-IDA 2000 column (MACHEREY - NAGEL). After elution with imidazole, the protein was cleaved with thrombin and loaded onto an Uno S column (Bio-Rad) and eluted with a salt gradient (0.5 M - 1 M NaCl). The eluted PB2 middle domain was not dissolved well under 500 mM NaCl concentration. To obtain more soluble domain, we introduced two mutations on the surface of this domain: P453H and I471T. The final protein was then concentrated to 10 mg/ml in 50 mM Tris-HCl (pH 8.0), 200 mM NaCl and 2 mM DTT and stored at -80°C. At N-terminal and C-terminal, there are additional four residues each 314,GSHM317 and 481GSGC484, respectively.


Crystals were grown using the hanging-drop vapor diffusion method. The protein solution was mixed with an equal volume of well solution (1.2 M NaCl and 2.5% (v/v) ethanol) and incubated at 4°C.

Data collection and structure determination

Crystals were picked up using a nylon loop. They were then dipped in mother liquor containing 20% (v/v) ethyleneglycol as a cryoprotectant and plunged into a nitrogen-gas stream at 100 K. The data were collected using an X-ray wavelength of 1.54 Å using Micro7HFM RAXISVII. The diffraction images were indexed, integrated and scaled using HKL2000 program [26]. The crystal space group was determined to be R32. Initial phase was obtained by molecular replacement (phaser) using H3N2 cap-binding domain structure 2VQZ [27]. The structure was refined using phenix.refine restraint refinement and TLS refinement [28]. Model building and manual refinement was done by Coot [29]. Comparison of the structures was done using PyMOL [30]. Data statistics such as Rmerge, Rmeas, Rpim and CC1/2 were obtained by Xtriage of phenix [31].

The missing residues of electron density are G314 (N-terminal) and 481GSGC484 (C-terminal) in native structure and 314GSHMRS319 (N-terminal) and 481GSGC484 (C-terminal) in m7GTP structure, respectively.

Accession Numbers

Coordinates and structure factors of PB2 middle domain with two amino acids mutation (P453H and I471T) have been deposited in the Protein Data Bank. The accession numbers of the structure without m7GTP and with m7GTP are 3WI0 and 3WI1, respectively. Additionally, wild type of PB2 middle domain without m7GTP has been deposited with the accession number 4J2R (This is not mentioned in this manuscript, but it is related structure of this manuscript.).


The influenza (A/PR/8/34) RNA polymerase PB2 plasmid, pBMSA-PB2, was provided by the DNA Bank, RIKEN BioResource Center (Tsukuba, Japan; originally deposited by Dr. Susumu Nakada) with the support of National Bio-Resources Project of the MEXT. We thank Prof. Nobuo SHIMAMOTO and Dr. Hideki Nakayama for the advice on a subcloning technique. We also thank the staff at KEK-PF for the data collection.

Author Contributions

Conceived and designed the experiments: TT HT. Performed the experiments: TT HQ YT HT. Analyzed the data: TT TY HT. Wrote the manuscript: TT HT. Discussion of the manuscript: TT TY DH TK HT.


  1. 1. Reid AH, Taubenberger JK, Fanning TG (2001) The 1918 Spanish influenza: integrating history and biology. Microbes Infect 3: 81-87. doi:10.1016/S1286-4579(00)01351-4. PubMed: 11226857.
  2. 2. Elton D, Digard P, Tiley L, Ortin J (2005) Structure and function of the influenza virus RNP. In: Y. Kawaoka, editor. In Current Topics in Influenza Virology. Horizon Scientific,Norfork.
  3. 3. Plotch SJ, Bouloy M, Ulmanen I, Krug RM (1981) A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 23: 847-858. doi:10.1016/0092-8674(81)90449-9. PubMed: 6261960.
  4. 4. Arranz R, Coloma R, Chichón FJ, Conesa JJ, Carrascosa JL et al. (2012) The structure of native influenza virion ribonucleoproteins. Science 338: 1634-1637. doi:10.1126/science.1228172. PubMed: 23180776.
  5. 5. Moeller A, Kirchdoerfer RN, Potter CS, Carragher B, Wilson IA (2012) Organization of the influenza virus replication machinery. Science 338: 1631-1634. doi:10.1126/science.1227270. PubMed: 23180774.
  6. 6. Tarendeau F, Crepin T, Guilligay D, Ruigrok RW, Cusack S et al. (2008) Host determinant residue lysine 627 lies on the surface of a discrete, folded domain of influenza virus polymerase PB2 subunit. PLoS Pathog 4: e1000136. PubMed: 18769709.
  7. 7. Obayashi E, Yoshida H, Kawai F, Shibayama N, Kawaguchi A et al. (2008) The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 454: 1127-1131. doi:10.1038/nature07225. PubMed: 18660801.
  8. 8. He X, Zhou J, Bartlam M, Zhang R, Ma J et al. (2008) Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 454: 1123-1126. doi:10.1038/nature07120. PubMed: 18615018.
  9. 9. Dias A, Bouvier D, Crépin T, McCarthy AA, Hart DJ et al. (2009) The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458: 914-918. doi:10.1038/nature07745. PubMed: 19194459.
  10. 10. Sugiyama K, Obayashi E, Kawaguchi A, Suzuki Y, Tame JR et al. (2009) Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J 28: 1803-1811. doi:10.1038/emboj.2009.138. PubMed: 19461581.
  11. 11. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J et al. (2009) Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458: 909-913. doi:10.1038/nature07720. PubMed: 19194458.
  12. 12. Subbarao EK, Kawaoka Y, Murphy BR (1993) Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation. J Virol 67: 7223-7228. PubMed: 8230444.
  13. 13. Hatta M, Gao P, Halfmann P, Kawaoka Y (2001) Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293: 1840-1842. doi:10.1126/science.1062882. PubMed: 11546875.
  14. 14. Steel J, Lowen AC, Mubareka S, Palese P (2009) Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog 5: e1000252. PubMed: 19119420.
  15. 15. Kuzuhara T, Kise D, Yoshida H, Horita T, Murazaki Y et al. (2009) Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding domain containing the pathogenicity-determinant lysine 627 residue. J Biol Chem 284: 6855-6860. PubMed: 19144639.
  16. 16. Honda A, Mizumoto K, Ishihama A (1999) Two separate sequences of PB2 subunit constitute the RNA cap-binding site of influenza virus RNA polymerase. Genes Cells 4: 475-485. doi:10.1046/j.1365-2443.1999.00275.x. PubMed: 10526235.
  17. 17. Li ML, Rao P, Krug RM (2001) The active sites of the influenza cap-dependent endonuclease are on different polymerase subunits. EMBO J 20: 2078-2086. doi:10.1093/emboj/20.8.2078. PubMed: 11296240.
  18. 18. Fechter P, Mingay L, Sharps J, Chambers A, Fodor E et al. (2003) Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding. J Biol Chem 278: 20381-20388. doi:10.1074/jbc.M300130200. PubMed: 12646557.
  19. 19. Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T et al. (2008) The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 15: 500-506. doi:10.1038/nsmb.1421. PubMed: 18454157.
  20. 20. Liu Y, Qin K, Meng G, Zhang J, Zhou J et al. (2013) Structural and functional characterization of K339T substitution identified in the PB2 subunit cap-binding pocket of influenza A virus. J Biol Chem 288: 11013-11023. doi:10.1074/jbc.M112.392878. PubMed: 23436652.
  21. 21. Karplus PA, Diederichs K (2012) Linking crystallographic model and data quality. Science 336: 1030-1033. doi:10.1126/science.1218231. PubMed: 22628654.
  22. 22. Holm L, Sander C (1991) Database algorithm for generating protein backbone and side-chain co-ordinates from a C alpha trace application to model building and detection of co-ordinate errors. J Mol Biol 218: 183-194. doi:10.1016/0022-2836(91)90883-8. PubMed: 2002501.
  23. 23. Miotto O, Heiny A, Tan TW, August JT, Brusic V (2008) Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by large-scale mutual information analysis. BMC Bioinformatics 9 Suppl 1: S18. doi:10.1186/1471-2105-9-S9-S18. PubMed: 18315849.
  24. 24. Le QM, Sakai-Tagawa Y, Ozawa M, Ito M, Kawaoka Y (2009) Selection of H5N1 influenza virus PB2 during replication in humans. J Virol 83: 5278-5281. doi:10.1128/JVI.00063-09. PubMed: 19264775.
  25. 25. Mänz B, Brunotte L, Reuther P, Schwemmle M (2012) Adaptive mutations in NEP compensate for defective H5N1 RNA replication in cultured human cells. Nat Commun 3: 802. doi:10.1038/ncomms1804. PubMed: 22549831.
  26. 26. Otwinowski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode. New York: Academic Press.
  27. 27. Vagin A, Teplyakov A (2010) Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 66: 22-25. doi:10.1107/S0108767309045206. PubMed: 20057045.
  28. 28. Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW et al. (2012) Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 68: 352-367. doi:10.1107/S0108767312007234. PubMed: 22505256.
  29. 29. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132. doi:10.1107/S0907444904019158. PubMed: 15572765.
  30. 30. DeLano L (2002) The PyMOL User's Manual. San Carlos, CA, USA.: DeLano Scientific.
  31. 31. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221. doi:10.1107/S0907444909052925. PubMed: 20124702.